SeattleGenetics®

Fact Sheet

FEBRUARY 2018

Empowered

THERAPIES • ANTIBODIES • SCIENCE

ADCETRIS®
(brentuximab vedotin)
Quick Facts

- Antibody-drug conjugate that targets CD30, which is expressed in classical Hodgkin lymphoma as well as other types of lymphoma
- Approved in the U.S. for four indications for treatment of adult patients:
  - Relapsed classical Hodgkin lymphoma
  - Relapsed systemic anaplastic large cell lymphoma (ALCL)
  - Classical HL post-auto-HSCT consolidation
  - Relapsed primary cutaneous ALCL and CD30-expressing mycosis fungoides
- Received Breakthrough Therapy Designation from FDA in frontline advanced classical Hodgkin lymphoma based on positive phase 3 ECHELON-1 trial data; FDA has accepted our sBLA for filing and granted Priority Review with a PDUFA date of May 1, 2018
- Only drug FDA-approved specifically for systemic anaplastic large cell lymphoma
- Seattle Genetics has full commercialization rights in the U.S. and Canada
- Under our collaboration with Takeda Pharmaceutical Company Limited, ADCETRIS is commercially available in 70 countries

Seattle Genetics is an emerging global multi-product biotechnology company that develops and commercializes innovative targeted therapies for the treatment of cancer. The company's industry-leading antibody-drug conjugate (ADC) technology harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. In addition to one marketed product, we are advancing a robust product pipeline of novel therapies for solid tumors and blood-related cancers designed to address significant unmet medical needs. Through internal research and development, collaborations and scientific innovation, we are committed to improving treatment outcomes for patients.

ADCETRIS: Broad Global Development Plan

We believe that our lead program, ADCETRIS® (brentuximab vedotin), has the potential to be the foundation of care for CD30-expressing lymphomas. We are executing a broad global development plan for potential indications in earlier lines of therapy and other CD30-expressing lymphomas. Across both corporate and investigator trials, ADCETRIS is being evaluated as a single-agent or in combination treatment in more than 70 clinical trials.

Positive results from the ECHELON-1 phase 3 clinical trial evaluating ADCETRIS in combination with chemotherapy in frontline advanced classical Hodgkin lymphoma were featured in a Plenary Scientific Session at the December 2017 American Society of Hematology (ASH) Annual Meeting. The data were also simultaneously published online in the *New England Journal of Medicine*. In early January 2018, we announced the FDA accepted for filing and granted Priority Review of our supplemental Biologics License Application (sBLA) for ADCETRIS in this disease setting, for which the agency previously granted Breakthrough Therapy Designation. This represents a significant milestone in our goal to redefine the frontline treatment of advanced Hodgkin lymphoma.

Advancing our Robust Pipeline

ADCs continue to advance as an important therapeutic modality, both as single agents and as part of various combination regimens for both hematologic malignancies and solid tumors. ADCETRIS is one of more than 20 proprietary and collaborator ADC programs in clinical development using our technology.

Our pipeline includes two ADC programs in ongoing or planned potentially registrational trials, enfortumab vedotin for urothelial cancer under our collaboration with Astellas and tisotumab vedotin for cervical cancer under our collaboration with Genmab. Additionally, we have multiple clinical trials ongoing and planned with ladiratuzumab vedotin for triple negative breast cancer.

ADVANCING INDUSTRY-LEADING ADC Technology



Potential to Improve Patient Outcomes with Targeted Therapies

Our antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary industry-leading technology, we are able to optimize each ADC to potentially improve outcomes for patients.

In our ADCs, stable linkers attach a potent synthetic cell-killing (cytotoxic) agent to an antibody. The antibody is targeted against a specific tumor-associated receptor on cancer cell surfaces. Our linker systems release the cytotoxic agent once inside the targeted cells. This target-specific approach is intended to enhance antitumor activity and minimize toxic effects across mutliple tumor types.

By targeting specific tumor-associated receptors on the surface of cancer cells, ADCs have the potential to spare non-targeted cells and reduce toxic side effects.

As shown in the illustration above, other approaches to cancer treatment target pathways inside the cell or activate immune cells. Various combinations of these novel modalities are likely to be the future of treatment in oncology.

In addition to advancing our ADC research, we are applying our expertise in targets and antibodies to the area of immuno-oncology. We believe that through targeted killing of tumor cells and immunogenic cell death, ADCs could become the preferred partner for immuno-oncology agents, and are testing or plan to test brentuximab vedotin, enfortumab vedotin, tisotumab vedotin and ladiratuzumab vedotin in combinations with checkpoint inhibitors.

We have a collaboration and license agreement with Unum Therapeutics to develop and commercialize novel antibody-coupled T-cell receptor (ACTR) therapies. We also have a collaboration with Pieris Pharmaceuticals to develop multiple targeted bispecific immuno-oncology treatments. Additionally, we are conducting clinical trials with SEA-CD40, a novel immuno-oncology agent using our sugar-engineered antibody technology, and SGN-2FF, an oral small molecule.

Extending Our Opportunities through ADC Technology Collaborations

Beyond broad internal development of our antibody-drug conjugate technology, we have entered into collaborations with a number of industry-leading biotechnology and pharmaceutical companies. These licensing activities extend the reach of our technology as collaborators investigate numerous targets in many therapeutic areas. Across both internal and collaborator programs, there are more than 20 ADCs in clinical development using our technology.

In addition to extending the reach of our technology into additional programs, our ADC technology licensing agreements have generated more than $375 million to date. They also provide us with future pipeline opportunities through co-development or opt-in rights to new ADC product candidates.

Find more details on our ADC technology collaborator program at our website, SeattleGenetics.com.

abbvie · astellas · Celldex therapeutics · Genentech · Genmab · Pfizer · Progenics

Strong Oncology Pipeline

Brentuximab Vedotin

HODGKIN LYMPHOMA (HL)	ECHELON-1: Frontline classical HL	Phase 3: sBLA accepted for filing
	CHECKMATE 812: Relapsed HL (+ nivolumab)	Phase 3
	Frontline HL in patients 60+ (+ nivolumab)	Phase 2
	Second-line HL (+ nivolumab)	Phase 2
NON-HODGKIN LYMPHOMA (NHL)	ECHELON-2: Frontline CD30-expressing mature T-cell lymphoma (MTCL) (also known as PTCL)	Phase 3: Data expected in 2018
	Relapsed NHL (+ nivolumab)	Phase 1/2

Other Programs

SOLID TUMORS		
Enfortumab vedotin*	Urothelial cancer post-checkpoint inhibitor	Phase 3: Planned
	EV-201: Urothelial cancer	Phase 2: Potentially registrational
	EV-103: First-line urothelial cancer (+ checkpoint inhibitor)	Phase 1b
Tisotumab vedotin**	Cervical cancer	Phase 2: Potentially registrational
	First-line cervical cancer (combination)	Phase 2: Planned
	Other solid tumors	Phase 2: Planned
Ladiratuzumab vedotin (SGN-LIV1A)	I-SPY 2: HER2-negative breast cancer	Phase 2
	Triple negative breast cancer (TNBC) (+ pembrolizumab)	Phase 1b/2
	TNBC (+ atezolizumab)	Phase 1b/2
	Breast cancer	Phase 1
LYMPHOMA		
Denintuzumab mafodotin	Diffuse large B-cell lympyhoma	Phase 2
SGN-CD19B	Non-Hodgkin lymphoma	Phase 1
LEUKEMIA		
SGN-CD123A	Acute myeloid leukemia	Phase 1
MYELOMA		
SGN-CD352A	Multiple myeloma	Phase 1
SGN-CD48A	Multiple myeloma	Phase 1
IMMUNO-ONCOLOGY		
SEA-CD40	Advanced cancer (+/- checkpoint inhibitor)	Phase 1
SGN-2FF	Advanced solid tumors	Phase 1
ACTR-BCMA	Multiple myeloma	Phase 1

* Program being developed in collaboration with Astellas ** Program being developed in collaboration with Genmab

These are investigational uses/agents and efficacy/safety have not been established.
Visit SeattleGenetics.com for the most current pipeline status and clinical trial details.

SeattleGenetics®

SEATTLE GENETICS, INC.
21823 30TH DRIVE SOUTHEAST
BOTHELL, WASHINGTON 98021
www.SeattleGenetics.com

Senior Management

Clay B. Siegall, Ph.D.
PRESIDENT & CHIEF EXECUTIVE OFFICER

Jonathan Drachman, M.D.
CHIEF MEDICAL OFFICER AND EXECUTIVE VICE PRESIDENT, RESEARCH AND DEVELOPMENT

Vaughn B. Himes, Ph.D.
CHIEF TECHNICAL OFFICER

Todd E. Simpson
CHIEF FINANCIAL OFFICER

Darren Cline
EXECUTIVE VICE PRESIDENT, COMMERCIAL

Jean I. Liu, J.D.
GENERAL COUNSEL, EXECUTIVE VICE PRESIDENT, LEGAL AFFAIRS

Christopher Pawlowicz
EXECUTIVE VICE PRESIDENT, HUMAN RESOURCES

Elaine Waller, Pharm.D.
EXECUTIVE VICE PRESIDENT, REGULATORY AFFAIRS

Board of Directors

Clay B. Siegall, Ph.D.
PRESIDENT, CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD OF DIRECTORS, SEATTLE GENETICS, INC.

Srinivas Akkaraju, M.D., Ph.D.
FOUNDER AND MANAGING GENERAL PARTNER AT SAMSARA BIOCAPITAL

Felix J. Baker, Ph.D.
CO-MANAGING MEMBER OF BAKER BROS. ADVISORS

David W. Gryska
EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, INCYTE CORPORATION

Marc E. Lippman, M.D.
KATHLEEN AND STANLEY GLASER PROFESSOR AND DEPUTY DIRECTOR, SYLVESTER COMPREHENSIVE CANCER CENTER, UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE

John A. Orwin
CHIEF EXECUTIVE OFFICER, RELYPSA, INC.

Nancy A. Simonian, M.D.
CHIEF EXECUTIVE OFFICER, SYROS PHARMACEUTICALS, INC.

Daniel G. Welch
EXECUTIVE PARTNER, SOFINNOVA VENTURES

Recent Highlights

- February 2018: Announced collaboration and license agreement with Pieris Pharmaceuticals with the goal of developing multiple targeted bispecific immuno-oncology treatments for solid tumors and blood cancers
- February 2018: Completed a common stock offering with gross proceeds of approximately $690M, intended to fund our planned acquisition of Cascadian Therapeutics
- January 2018: Announced our proposed acquisition of Cascadian Therapeutics, adding a late-stage breast cancer program to enhance our solid tumor programs with potential rapid registrational pathways
- January 2018: ADCETRIS® (brentuximab vedotin) received European Commission approval for CD30-positive CTCL after at least one prior systemic therapy
- January 2018: Announced the FDA accepted our supplemental Biologics License Application for ADCETRIS in frontline advanced Hodgkin lymphoma and granted Priority Review; PDUFA action date May 1, 2018
- December 2017: Highlighted data from broad ADCETRIS development program in 18 abstracts accepted for presentation at the American Society of Hematology (ASH) Annual Meeting, including phase 3 ECHELON-1 clinical trial results in Plenary Scientific Session
- December 2017: Presented updated phase 1 data of ladiratuzumab vedotin (SGN-LIV1A) in patients with TNBC at 2017 San Antonio Breast Cancer Symposium
- November 2017: Announced fourth US approval of ADCETRIS for primary cutaneous ALCL and CD30-expressing mycosis fungoides, the most common subtypes of cutaneous T-cell lymphoma

SGEN Quick Facts

NASDAQ SYMBOL
SGEN

CASH AND INVESTMENTS
$413 million as of December 31, 2017

COMMON STOCK OUTSTANDING
Approximately 157.9 million shares

FISCAL YEAR END
December 31

YEAR FOUNDED
1998

EMPLOYEES
>1,000

GLOBAL HEADQUARTERS
Bothell, WA USA

EUROPEAN OFFICES
Zug, Switzerland

INVESTORS
Peggy Pinkston, 425.527.4160
Investors@seagen.com

MEDIA
Media@seagen.com

TECHNOLOGY LICENSING
BusinessDevelopment@seagen.com

GENERAL INQUIRIES
Contact@seagen.com

FOLLOW US ON TWITTER
@SeattleGenetics

 Certain of the statements made in this fact sheet and elsewhere are forward looking. These statements are based on factors that involve risks and uncertainties, and actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks and uncertainties associated with fulfilling sales, marketing and distribution requirements; the acceptance of ADCETRIS in the marketplace; the status of reimbursement from third-party payors; risks inherent in clinical stage development and risks that our collaborators do not fulfill their obligations. For additional information on these and other factors that could affect Seattle Genetics' results, see the reports filed by the company with the SEC, which are available at www.sec.gov. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.